Renteria-Flores F, Garcia-Chagollan M, Jave-Suarez L
Vaccines (Basel). 2024; 12(9).
PMID: 39340000
PMC: 11435753.
DOI: 10.3390/vaccines12090968.
Wang L, Hu J, Li K, Zhao Y, Zhu M
iScience. 2024; 27(9):110791.
PMID: 39286511
PMC: 11403445.
DOI: 10.1016/j.isci.2024.110791.
Theys J, Patterson A, Mowday A
Mol Diagn Ther. 2024; 28(2):141-151.
PMID: 38302842
PMC: 10925577.
DOI: 10.1007/s40291-024-00695-0.
Roe J, Seely K, Bussard C, Eischen Martin E, Mouw E, Bayles K
Pharmaceutics. 2023; 15(7).
PMID: 37514190
PMC: 10384176.
DOI: 10.3390/pharmaceutics15072004.
Thakker D, Narayanan R
Med Oncol. 2023; 40(6):175.
PMID: 37171497
DOI: 10.1007/s12032-023-02043-4.
Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma.
Doroud D, Hozouri H
Iran Biomed J. 2022; 26(5):340-9.
PMID: 36369747
PMC: 9763876.
DOI: 10.52547/ibj.3676.
Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy.
Gupta K, Nowicki C, Giurini E, Marzo A, Zloza A
Vaccines (Basel). 2021; 9(12).
PMID: 34960243
PMC: 8707929.
DOI: 10.3390/vaccines9121497.
Oncolytic Bacteria and their potential role in bacterium-mediated tumour therapy: a conceptual analysis.
Wang Y, Guo W, Wu X, Zhang Y, Mannion C, Brouchkov A
J Cancer. 2019; 10(19):4442-4454.
PMID: 31528208
PMC: 6746139.
DOI: 10.7150/jca.35648.
Efficacy of Tumor-Targeting A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models.
Murakami T, Hiroshima Y, Miyake K, Kiyuna T, Endo I, Zhao M
Cells. 2019; 8(6).
PMID: 31208120
PMC: 6628209.
DOI: 10.3390/cells8060599.
Tumour-targeting bacteria engineered to fight cancer.
Zhou S, Gravekamp C, Bermudes D, Liu K
Nat Rev Cancer. 2018; 18(12):727-743.
PMID: 30405213
PMC: 6902869.
DOI: 10.1038/s41568-018-0070-z.
-NT in cancer therapy.
Staedtke V, Roberts N, Bai R, Zhou S
Genes Dis. 2018; 3(2):144-152.
PMID: 30258882
PMC: 6150096.
DOI: 10.1016/j.gendis.2016.01.003.
Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth.
He L, Yang H, Liu F, Chen Y, Tang S, Ji W
Oncotarget. 2017; 8(49):85772-85782.
PMID: 29156755
PMC: 5689645.
DOI: 10.18632/oncotarget.20486.
Small molecule signaling, regulation, and potential applications in cellular therapeutics.
McNerney M, Styczynski M
Wiley Interdiscip Rev Syst Biol Med. 2017; 10(2).
PMID: 28960879
PMC: 5899512.
DOI: 10.1002/wsbm.1405.
Intracellular delivery of biologic therapeutics by bacterial secretion systems.
Walker B, Stan G, Polizzi K
Expert Rev Mol Med. 2017; 19:e6.
PMID: 28382885
PMC: 5479498.
DOI: 10.1017/erm.2017.7.
32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect.
Chandra D, Chellakkan Selvanesan B, Yuan Z, Libutti S, Koba W, Beck A
Oncotarget. 2017; 8(13):20729-20740.
PMID: 28186976
PMC: 5400540.
DOI: 10.18632/oncotarget.15117.
Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress.
Mowday A, Guise C, Ackerley D, Minton N, Lambin P, Dubois L
Cancers (Basel). 2016; 8(7).
PMID: 27367731
PMC: 4963805.
DOI: 10.3390/cancers8070063.
Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.
Cronin M, Le Boeuf F, Murphy C, Roy D, Falls T, Bell J
Mol Ther. 2014; 22(6):1188-1197.
PMID: 24569832
PMC: 4048890.
DOI: 10.1038/mt.2014.23.
Bacteria and tumours: causative agents or opportunistic inhabitants?.
Cummins J, Tangney M
Infect Agent Cancer. 2013; 8(1):11.
PMID: 23537317
PMC: 3668256.
DOI: 10.1186/1750-9378-8-11.
High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting.
Cronin M, Akin A, Collins S, Meganck J, Kim J, Baban C
PLoS One. 2012; 7(1):e30940.
PMID: 22295120
PMC: 3266281.
DOI: 10.1371/journal.pone.0030940.
Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors.
Krick E, Sorenmo K, Rankin S, Cheong I, Kobrin B, Thornton K
Am J Vet Res. 2011; 73(1):112-8.
PMID: 22204296
PMC: 4596235.
DOI: 10.2460/ajvr.73.1.112.